Quality of life (QoL) and International Normalized Ratio (INR) control of patients attending anticoagulation clinics

Public Health

Volumn 129, Issue 7, 2015, Pages 954-962

  Hasan, S S ^a   Teh, K M ^b   Ahmed, S I ^b   Chong, D W K ^d   Ong, H C ^b   Naina, B ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^c HOSPITAL KUALA LUMPUR   (Malaysia)

^d MONASH UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

Anticoagulation therapy; International Normalized Ratio; Quality of life

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT; MEDICINE; PUBLIC HEALTH; QUALITY OF LIFE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DUKE ANTICOAGULATION SATISFACTION SCALE; FEMALE; HEALTH STATUS; HEALTH SURVEY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALAYSIAN; MALE; PHYSICAL ACTIVITY; QUALITY CONTROL; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; SHORT FORM 12; URBAN AREA; AGE DISTRIBUTION; AMBULATORY CARE; ASIAN CONTINENTAL ANCESTRY GROUP; MALAYSIA; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OUTPATIENT; PROCEDURES; PSYCHOLOGY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALAYSIA; MALE; MIDDLE AGED; OUTPATIENTS; QUALITY OF LIFE; SEX DISTRIBUTION; SURVEYS AND QUESTIONNAIRES; WARFARIN;

EID: 84941599930     PISSN: 00333506     EISSN: 14765616     Source Type: Journal    
DOI: 10.1016/j.puhe.2015.05.014     Document Type: Article

References (47)

1. Lacy C.F., Armstrong L.L., Goldman M.P., Lance L.L. Drug information handbook 2008, Lexi-Comp, USA. 17th ed.
2. Sameerah S.A.R., Lian L.M. Malaysian statistics on medicines; 2006 2006, Available from:, [accessed 25.04.12]. http://pharmacy.gov.my/aeimages//File/MsiaStatMed2006B.pdf.
3. Ansell J., Hirsh J., Dalen J., Bussey H., Anderson D. Managing oral anticoagulant therapy. Chest 2001, 119:22S-38S.
4. Bussey H. Traditional anticoagulant therapy: why abandon half a century of success?. Am J Health Syst Pharm 2002, 59(Suppl. 6):S3-S6.
5. DiPiro J.T., Talbert R.T., Yee G.C., Matzke G.R., Wells B.G., Posey L.M. Pharmacotherapy: a pathophysiologic approach 2005, McGraw-Hill, USA. 6th ed.
6. Bayard Y.L., Ostermayer S.H., Sievert H. Alternatives to warfarin in atrial fibrillation: drugs and devices. Heart 2008, 94:1113-1116.
7. Fihn S.D., McDonell M., Martin D., Henikoff J., Vermes D., Kent D., et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993, 118:511-520.
8. Hirsh J., Fuster V., Ansell J., Halperin J.L. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003, 41:1633-1652.
9. Kimmel S.E. Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother 2008, 9(5):677-686.
10. Kneeland P.P., Fang M.C. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 2010, 4:51-60.
11. Landefeld C.S., Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989, 87:144-152.
12. Fiumara K., Goldhaber S.Z. A patient's guide to taking coumadin/warfarin. Circulation 2009, 119:e220-e222.
13. Kayser S.R. Practical challenges in the management of oral anticoagulation. Prog Cardiovasc Nurs 2005, 20(2):80-85.
14. Hasan S.S., Siow R.F., Ahmadi K., Kamarunnesa M.A., NurulZaidah B., Anwar M. Factors influencing concomitant use of complementary and alternative medicines and warfarin. J Pharm Pract Res 2010, 40(4):294-299.
15. Hyman B.T., Landas S.K., Ashman R.F., Schelper R.L., Robinson R.A. Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 1987, 82(6):1233-1237.
16. Myers S.P. Interactions between complementary medicines and warfarin. Aust Prescr 2002, 25:54-56.
17. Youssef S. Patients taking warfarin: problems revealed by medicines use reviews. Pharm J 2008, 280:662-667.
18. Wells P.S., Holbrook A.M., Crowther N.R., Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994, 121:676-683.
19. Ansell J., Hirsh J., Hylek E., Jacobson A., Crowther M., Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines, 8th edition. Chest 2008, 133:160S-198S.
20. Samsa G., Matchar D.B., Dolor R.J., Wiklund I., Hedner E., Wygant G., et al. A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. Health Qual Life Outcomes 2004, 2(22):1-11.
21. Failde I., Medina P., Ramirez C., Arana R. Construct and criterion validity of the SF-12 health questionnaire in patients with acute myocardial infarction and unstable angina. J Eval Clin Pract 2010, 16:569-573.
22. Gandek B., Ware J.E., Aaronson N.K., Apolone G., Bjorner J.B., Brazier J.E., et al. Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA project. J Clin Epidemiol 1998, 51:1171-1178.
23. Muller-Nordhorn J., Roll S., Willich S.N. Comparison of the short form (SF)-12 health status instrument with the SF-36 in patients with coronary heart disease. Heart 2004, 90:523-527.
24. Ware J.E., Kosinski M., Keller S.D. SF-36 physical and mental summary scales: a user's manual 1994, New England Medical Center, The Health Institute, Boston.
25. Ware J.E., Snow K.K., Kosinski M. SF-36 health survey. Manual and interpretation guide 1993, New England Medical Center, The Health Institute, Boston.
26. Jenkinson C., Chandola T., Coulter A., Bruster S. An assessment of the construct validity of SF 12 summary scores across ethnic groups. J Public Health Med 2001, 23(3):187-194.
27. Ware J.E., Kosinski M., Keller S.D. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34(3):220-233.
28. Anthi G., Konstantinos M., Mariana B., Evagellia D.A., George T. Instruments for measuring anticoagulation-related quality of life: modification, and preliminary validation. Haematology 2007, 10(2-3):129-141.
29. Hasan S.S., Shamala R., Syed I.A., Basariah N., Chong D.W., Mei T.K., et al. Factors affecting warfarin-related knowledge and INR control of patients attending physician- and pharmacist- managed anticoagulation clinics. J Pharm Pract 2011, 24(5):485-493.
30. Bajorek B.V., Ogle S.J., Duguid M.J., Shenfield G.M., Krass I. Balancing risk versus benefit: the elderly patient's perspective on warfarin therapy. Pharm Pract 2009, 7(2):113-123.
31. Douglas A. Current recommendations for warfarin therapy use and monitoring. Med Clin N Am 1998, 82(3):602-611.
32. Gibbar-Clements T., Shirrell D., Dooley R., Smiley B. The challenge of warfarin therapy. Am J Nurs 2000, 100(3):38-40.
33. Gitter M.J., Jaeger T.M., Petterson T.M., Gersh B.J., Silverstein M.D. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rocherster, Minnesota. Mayo Clin Proc 1995, 70:725-733.
34. Greenblatt D.J., von Moltke L.L. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 2005, 45:127-132.
35. Triplett D.A. Current concepts for warfarin therapy: use and monitoring. Med Clin N Am 1998, 82(3):601-612.
36. Brigden M.L. Oral anticoagulant therapy. Postgrad Med J 1996, 99:81-102.
37. Paquette M., Roy D., Talajic M., Newman D., Couturier A., Yang C., et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol 2000, 86:764-768.
38. Fang M.C., Machtinger E.L., Wang F., Schillinger D. Health literacy and anticoagulation-related outcomes among patients taking warfarin. J Gen Intern Med 2006, 21:841-846.
39. Hylek E.M., Evans-molina C., Shea C., Henault L.E., Regan S. Major haemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007, 115:2689-2696.
40. Borosak M., Choo S. Warfarin: balancing the benefits and harms. Aust Prescr 2004, 27:88-92.
41. Campbell P., Roberts G., Eaton V., Coghlan D. Managing warfarin therapy in the community. Aust Prescr 2001, 24:86-89.
42. Hirsh J., Dalen J.E., Anderson D.R., Poller L., Bussey H., Ansell J., et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001, 119:8S-21S.
43. Holbrook A.M., Pereira J.A., Labiris R., Douketis J.D., Crowther M., Wells P.S. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005, 165:1095-1106.
44. Gomberg-Maitland M., Wenger N.K., Feyzi J., Lengyel M., Volgman A.S., Petersen P., et al. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J 2006, 27(16):1947-1953.
45. Thomson R., Robinson A., Greenaway J., Lowe P. Development and description of a decision analysis based decision support tool for stroke prevention in atrial fibrillation. Qual Saf Health Care 2002, 11(1):25-31.
46. Daniel E.S., Anne S.H., Jonathan P.P., Kenneth W.M., Yuliya L., Guohua P., et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical Trial. J Am Heart Assoc 2013, 2:e000067. 10.1161/JAHA.112.000067.
47. Rose A.J., Berlowitz D.R., Miller D.R., Hylek E.M., Ozonoff A., Zhao S., et al. INR targets and site-level anticoagulation control: results from the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2012, 10:590-595.